Medicare GLP-1 coverage (BALANCE transitional model, July 2026)
It's a powerful aid, not a replacement for healthy habits
The Substances on the Table These are the drugs being reviewed and the medical uses FDA will be evaluating: July 23, 2026: BPC-157 (free base and acetate) ulcerative colitis KPV (free base and acetate) wound healing and inflammatory conditions TB-500 (free base and acetate) wound healing MOTs-C (free base and acetate) obesity and osteoporosis July 24, 2026: Emideltide / DSIP (delta sleep-inducing peptide, free base and acetate) opioid withdrawal, chronic insomnia, and narcolepsy Semax (free base and acetate) cerebral ischemia, migraine, and trigeminal neuralgia Epitalon (free base and acetate) insomnia If any or all of these substances are added to the 503A Bulks List following this process, it would formalize the legal pathway for licensed pharmacists and physicians to compound them for patients
GLP-1 receptor agonists enhance insulin secretion by interacting with GLP-1 receptors in pancreatic beta cells
GLP-1 Boost is designed to enhance your bodys own GLP-1 production for better hunger control and energy
Rapado-Castro, M
.png)
